Therapeutic

Breast cancer vaccine: safe at Phase I trial

Breast cancer vaccine: safe at Phase I trial

A study in JAMA Oncology in November 2022 suggests that researchers in the US are making progress with an experimental vaccine against breast cancer. Led by Dr Mary (Nora) L. Disis of the University of Washington Medicine Cancer Vaccine Institute, the team indicate...

Exclusive interview with Dr Christian Brander

Exclusive interview with Dr Christian Brander

Another highlight from this year's World Vaccine Congress in Europe was the opportunity to speak to Dr Christian Brander in person. Co-founder and Chief Scientific Officer at Aelix Therapeutics; he and his team are based in Spain, focusing on a therapeutic HIV...

LUMC and ISA study generates “strong” results

LUMC and ISA study generates “strong” results

A publication in the Journal for ImmunoTherapy of Cancer in October 2022 by researchers at the Leiden University Medical Centre (LUMC) investigated the safety and immunogencity of ISA Pharmaceuticals’ Amplivant adjuvant and Synthetic Long Peptide (SLP) therapeutic...

Senescent cell potential against cancer revealed

Senescent cell potential against cancer revealed

Researchers in Europe published results in Cancer Discovery in November 2022 that indicate promising responses to vaccination with senescent cells. The researchers suggest that these cells “combine several features that render them highly efficient in activating...

BioNTech founding duo anticipate mRNA against cancer

BioNTech founding duo anticipate mRNA against cancer

Speaking to the BBC’s Laura Kuenssberg on the Sunday programme in October 2022, Professors Ugur Sahin and Ozlem Tureci indicated that mRNA treatments against various cancers could be available as soon as 2030. The professors co-founded the German company BioNTech in...

Cancer therapy or prevention: where should we focus?

Cancer therapy or prevention: where should we focus?

An article in the New York Times in October 2022 reflects that developing a cancer vaccine for high-risk patients seems like an “impossible dream”. However, recent steps suggest that we may be closer to this possibility than previously thought. While these...

Mouse model mRNA success for hereditary tyrosinemia 1

Mouse model mRNA success for hereditary tyrosinemia 1

A German study published in September 2022 in Molecular Therapy supports a clinical trial of “periodic low-dose intramuscular administration” of an mRNA-based therapy against Hereditary tyrosinemia 1. This is a recessive genetic disease of amino acid metabolism,...